TY  - BOOK
AU  - Gliebus,Gediminas Peter
TI  - Progressive cognitive impairment and its neuropathologic correlates
T2  - Neurodevelopmental diseases--laboratory and clinical research
SN  - 9781634852975
AV  - RC365 
U1  - 616.8/047 23
PY  - 2016///]
CY  - New York
PB  - Nova Biomedical
KW  - Nervous system
KW  - Degeneration
KW  - Neurodegenerative Diseases
KW  - HEALTH & FITNESS / Diseases / General
KW  - bisacsh
KW  - MEDICAL / Clinical Medicine
KW  - MEDICAL / Diseases
KW  - MEDICAL / Evidence-Based Medicine
KW  - MEDICAL / Internal Medicine
KW  - fast
KW  - Electronic books
N1  - Includes bibliographical references and index; PROGRESSIVE COGNITIVE IMPAIRMENT AND ITS NEUROPATHOLOGIC CORRELATES; PROGRESSIVE COGNITIVE IMPAIRMENT AND ITS NEUROPATHOLOGIC CORRELATES; Library of Congress Cataloging-in-Publication Data; CONTENTS; FOREWORD; INTRODUCTION; Chapter 1: NEUROPATHOLOGY OF NEURODEGENERATIVE DISORDERS; ABSTRACT; BRAIN EXAMINATION AND SECTIONS; ALZHEIMER DISEASE NEUROPATHOLOGIC CHANGE; LEWY BODY DISEASE; FRONTOTEMPORAL LOBAR DEGENERATION; PICK DISEASE (FTLD-TAU, PID); PROGRESSIVE SUPRANUCLEAR PALSY (FTLD-TAU, PSP); CORTICOBASAL DEGENERATION (FTLD-TAU, CBD); FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP-43 PROTEINOPATHY (FTLD-TDP)FTLD-FUS; PRION DISEASE; SUMMARY; REFERENCES; Chapter 2: IMAGING AND CEREBROSPINAL FLUID BIOMARKERS IN ALZHEIMER'S DISEASE AND LEWY BODY SPECTRUM DISORDERS; ABSTRACT; GLOSSARY; 1. INTRODUCTION; 2. BIOMARKERS DERIVED FROM STRUCTURAL MAGNETIC RESONANCE IMAGING (MRI) IN AD AND LBD; 2.1. Cross-sectional Profiles of Cerebral Atrophy; 2.2. Longitudinal Rates of Cerebral Atrophy; 2.3. Atrophy Patterns in Medial Temporal Lobe Structures; 2.3.1. Hippocampus; 2.3.2. Entorhinal Cortex; 2.3.3. Subcortical Structures; 2.4. White Matter Hyperintensities3. BIOMARKERS DERIVED FROM DIFFUSION TENSOR IMAGING (DTI) IN AD AND LBD; 4. BIOMARKERS DERIVED FROM POSITRON EMISSION TOMOGRAPHY (PET) IN AD AND LBD; 4.1. Role of FDG-PET; 4.2. Role of Amyloid PET; 4.3. Role of Acetylcholine Esterase Activity on PET; 5. BIOMARKERS DERIVED FROM SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) IN AD AND LBD; 6. PROTON MAGNETIC RESONANCE SPECTROSCOPY (1H-MRS) AS A BIOMARKER IN AD AND LBD; 7. BIOMARKERS DERIVED FROM FUNCTIONAL MAGNETIC RESONANCE IMAGING (FMRI) IN AD AND LBD; 8. [123I]METAIODOBENZYLGUANIDINE ([123I]MIBG) MYOCARDIAL SCINTIGRAPHY TO ASSESS AUTONOMIC DYSFUNCTION IN AD AND LBD9. CEREBROSPINAL FLUID (CSF) BIOMARKERS IN AD AND LBD; CONCLUSION; ACKNOWLEDGMENTS; REFERENCES; Chapter 3: FUNCTION AND DYSFUNCTION OF THE PREFRONTAL LOBES IN NEURODEGENERATIVE DISEASES; ABSTRACT; TERMINOLOGY; NEUROANATOMY OF PREFRONTAL FUNCTIONS; Stuss' Model of Prefrontal Function; Cortico-Striato-Pallido-Thalamo-Cortical Loops; Integration of the Two Models; Larger-Scale Frontal Networks; CLINICAL ASSESSMENT OF PREFRONTAL FUNCTIONS; Dorsolateral Prefrontal Functions; Medial Prefrontal FunctionsOrbitofrontal Functions; Frontal Polar Functions; DISORDERS OF PREFRONTAL FUNCTIONS IN NEURODEGENERATIVE DISEASES; Subcortical Dementias; Behavioural Variant Frontotemporal Dementia (bvFTD); Behavioural/Dysexecutive Variant of Alzheimer's Disease; ACKNOWLEDGMENTS; REFERENCES; Chapter 4: ACTION-INTENTIONAL DISORDERS IN NEURODEGENERATIVE DISEASES; ABSTRACT; MOVEMENT-ACTION PROGRAMMING: "HOW" AND "WHEN"; RELATIONSHIPS BETWEEN COMPONENTS OF SENSORY-ATTENTION AND ACTION-INTENTION; ACTION-INTENTIONAL DISORDERS; Impaired Initiation; Akinesia; Defective Response Inhibition
UR  - https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1356586
ER  -